本文已被:浏览 581次 下载 329次
Received:January 10, 2021 Published Online:November 20, 2021
Received:January 10, 2021 Published Online:November 20, 2021
中文摘要: 目的 探讨我国自主研发免疫检查点抑制剂(ICI)联合化疗在晚期非小细胞肺癌(NSCLC)治疗中的疗效和安全性,为NSCLC诊治提供参考。方法 回顾性分析2019年10月至2020年12月于江苏省人民医院浦口分院肿瘤科收治68例EGFR/ALK野生型晚期NSCLC患者的临床资料,根据治疗方案分为联合组(32例)和化疗组(36例)。联合组给予PD-1抑制剂免疫治疗联合化疗,对照组给予常规化疗。比较两组患者疗效、客观缓解率(ORR)、疾病控制率(DCR)以及药物不良反应。结果 治疗后,联合组ORR高于化疗组(46.88% vs 19.44%,χ2=5.824,P<0.05),联合组DCR高于化疗组(87.50% vs 66.67%,χ2=4.087,P<0.05)。联合组发生2例甲状腺功能减退,2例皮肤毒性反应,为免疫相关不良反应。两组骨髓抑制、胃肠道反应、转氨酶升高等不良反应比较差异无统计学意义(P>0.05)。结论 对于晚期无驱动基因突变的NSCLC,化疗联合国产ICI免疫治疗疗效确切,不良反应患者可耐受。
Abstract:Objective To explore the efficacy and safety of domestic independent research on domestic immune checkpoint inhibitors (ICI) combined with chemotherapy in advanced non-small cell lung cancer (NSCLC), and to provide reference for diagnosis and treatment of NSCLC. Methods A retrospective analysis of 68 cases of EGFR/ALK wild-type advanced NSCLC admitted to the department of Oncology, Pukou Branch of Jiangsu Provincial Peoples Hospital from October 2019 to December 2020 were performed. The subjects were divided into combination group(n=32) and chemotherapy group(n=36) according to different treatment regimens. The combination group was given PD-1 inhibitor immunotherapy combined with chemotherapy, and the control group was given conventional chemotherapy. After treatment, the efficacy, objective remission rate (ORR), disease control rate (DCR), and adverse drug reactions of the two groups were compared. Results After treatment, the ORR (46.88% vs 19.44%)and DCR(87.50% vs 66.67%) in combined group were higher than those in chemotherapy group (P<0.05). Two cases of hypothyroidism and two cases of skin toxicity occurred in combined group, which were immune related adverse reactions. There was no significant difference in bone marrow suppression, gastrointestinal reaction and transaminase rise between the two groups (P>0.05). Conclusion For advanced NSCLC without driver gene mutations, chemotherapy and immunotherapy with domestic ICI are effective, and their adverse reactions can be tolerated.
keywords: Non-small cell lung cancer Immune checkpoint inhibitor Chemotherapy Immunotherapy Domestic Camrelizumab Sintilimab PD-1
文章编号: 中图分类号:R734.2 文献标志码:A
基金项目:
Author Name | Affiliation |
SUN Xu-dong, SUN Hui, FANG Yue-yu | Department of Oncology, Pukou Branch of Jiangsu Provincial Peoples Hospital, Nanjing, Jiangsu 211800, China |
Author Name | Affiliation |
SUN Xu-dong, SUN Hui, FANG Yue-yu | Department of Oncology, Pukou Branch of Jiangsu Provincial Peoples Hospital, Nanjing, Jiangsu 211800, China |
引用文本: